The lowering of the price target from $93 to $81 by Citigroup suggests a less optimistic outlook on Biomarin's stock performance, which could lead to a negative short-term impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target may influence investor sentiment negatively.